Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.43 |
| ▸ | HTR2A | P28223 | 9/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | TPO | P07202 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20992673 | 0.83 | PPARD (0.41) | PPARDPPARAIDO1 | |
| SCHEMBL4835664 | 0.80 | GAA (0.42) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL4830230 | 0.77 | GAA (0.54) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL19670055 | 0.74 | GAA (0.40) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL25376811 | 0.73 | SLC6A4 (0.36) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL9120134 | 0.73 | IDO1 (0.53) | SLC6A4KCNH2HTR2APPARDPPARA | |
| SCHEMBL13840653 | 0.73 | SLC6A4 (0.54) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL31062891 | 0.71 | MTNR1A (0.52) | PPARDPPARA | |
| SCHEMBL31063094 | 0.70 | CA2 (0.41) | GAAIDO1 | |
| SCHEMBL14201636 | 0.70 | KDM4E (0.38) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230023075-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20210346361-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-11 | — | — | US | disclosed |
| US-11154556-B2 | Methods of treating solid tumors with CCR2 antagonists | CHEMOCENTRYX, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3297438-B1 | CCR2 MODULATORS | CHEMOCENTRYX INC (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20190209573-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-11 | — | — | US | disclosed |
| WO-2019136368-A2 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| WO-2019060820-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160340356-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346361-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CCR2, CXCR2, CCRL2 | SLC6A4 3514/4885KCNH2 3829/4885HTR2A 1055/4885 |
| US-20190209573-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CCR2, CXCR2, CCRL2 | SLC6A4 3418/4885KCNH2 3915/4885HTR2A 917/4885 |
| US-11154556-B2 | Methods of treating solid tumors with CCR2 antagonists | CCR2, CXCR2, CCRL2 | SLC6A4 3418/4885KCNH2 3915/4885HTR2A 917/4885 |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | SLC6A4 2407/4885KCNH2 4753/4885HTR2A 348/4885 |
| US-20230023075-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | SLC6A4 4169/4885KCNH2 4737/4885HTR2A 1028/4885 |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | SLC6A4 4169/4885KCNH2 4737/4885HTR2A 1028/4885 |
| US-20160340356-A1 | CCR2 MODULATORS | CCR2, CCR1, CCR5 | SLC6A4 4017/4885KCNH2 4747/4885HTR2A 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.